BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu T, Wan Y, Xiao Y, Xia C, Duan G. Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. J Med Chem 2020;63:8977-9002. [PMID: 32320239 DOI: 10.1021/acs.jmedchem.0c00491] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Duan YC, Zhang SJ, Shi XJ, Jin LF, Yu T, Song Y, Guan YY. Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. Eur J Med Chem 2021;222:113588. [PMID: 34107385 DOI: 10.1016/j.ejmech.2021.113588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chen S, Tan J, Zhang A. The ups, downs and new trends of IDO1 inhibitors. Bioorg Chem 2021;110:104815. [PMID: 33773223 DOI: 10.1016/j.bioorg.2021.104815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jenke R, Reßing N, Hansen FK, Aigner A, Büch T. Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers (Basel) 2021;13:634. [PMID: 33562653 DOI: 10.3390/cancers13040634] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
4 Feng L, Wang G, Chen Y, He G, Liu B, Liu J, Chiang CM, Ouyang L. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives. Med Res Rev 2021. [PMID: 34633088 DOI: 10.1002/med.21859] [Reference Citation Analysis]
5 Zhou M, Yuan M, Zhang M, Lei C, Aras O, Zhang X, An F. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. Eur J Med Chem 2021;226:113825. [PMID: 34562854 DOI: 10.1016/j.ejmech.2021.113825] [Reference Citation Analysis]
6 Zhou H, Jiang J, Lu J, Ran D, Gan Z. Synthesis and biological evaluation of novel 2,4-dianilinopyrimidine derivatives as potent dual janus kinase 2 and histone deacetylases inhibitors. Journal of Molecular Structure 2022;1253:132200. [DOI: 10.1016/j.molstruc.2021.132200] [Reference Citation Analysis]
7 Wu S, Huang Y, Wang T, Li K, Lu J, Huang M, Dong G, Sheng C. Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy. J Med Chem 2022. [PMID: 35238576 DOI: 10.1021/acs.jmedchem.1c02026] [Reference Citation Analysis]
8 Sun M, Qin J, Kang Y, Zhang Y, Ba M, Yang H, Duan Y, Yao Y. 2-Methoxydiol derivatives as new tubulin and HDAC dual-targeting inhibitors, displaying antitumor and antiangiogenic response. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.105625] [Reference Citation Analysis]
9 Yan W, Ling L, Wu Y, Yang K, Liu R, Zhang J, Zhao S, Zhong G, Zhao S, Jiang H, Xie C, Cheng J. Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents. J Med Chem 2021;64:16573-97. [PMID: 34783558 DOI: 10.1021/acs.jmedchem.1c01155] [Reference Citation Analysis]
10 Ren Q, Gao W. Current status in the discovery of dual BET/HDAC inhibitors. Bioorg Med Chem Lett 2021;31:127671. [PMID: 33229136 DOI: 10.1016/j.bmcl.2020.127671] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Öner Y, Serrano M, Sarto P, Iguácel LP, Piquer-Sabanza M, Estrada O, Juan T, Calvo JH. Genome-Wide Association Studies of Somatic Cell Count in the Assaf Breed. Animals (Basel) 2021;11:1531. [PMID: 34074014 DOI: 10.3390/ani11061531] [Reference Citation Analysis]
12 Zhang Z, Xing X, Guan P, Song S, You G, Xia C, Liu T. Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies. Eur J Med Chem 2021;217:113314. [PMID: 33765606 DOI: 10.1016/j.ejmech.2021.113314] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Havare ÖÇ. Topological indices and QSPR modeling of some novel drugs used in the cancer treatment. Int J Quantum Chem 2021;121. [DOI: 10.1002/qua.26813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Cheshmazar N, Hemmati S, Hamzeh-Mivehroud M, Sokouti B, Zessin M, Schutkowski M, Sippl W, Nozad Charoudeh H, Dastmalchi S. Development of New Inhibitors of HDAC1-3 Enzymes Aided by In Silico Design Strategies. J Chem Inf Model 2022. [PMID: 35467871 DOI: 10.1021/acs.jcim.1c01557] [Reference Citation Analysis]
15 Rodrigues DA, Roe A, Griffith D, Chonghaile TN. Advances in the Design and Development of PROTAC-mediated HDAC degradation. Curr Top Med Chem 2021. [PMID: 34649488 DOI: 10.2174/1568026621666211015092047] [Reference Citation Analysis]
16 Toulouse JL, Shi G, Lemay-St-Denis C, Ebert MCCJC, Deon D, Gagnon M, Ruediger E, Saint-Jacques K, Forge D, Vanden Eynde JJ, Marinier A, Ji X, Pelletier JN. Dual-Target Inhibitors of the Folate Pathway Inhibit Intrinsically Trimethoprim-Resistant DfrB Dihydrofolate Reductases. ACS Med Chem Lett 2020;11:2261-7. [PMID: 33214838 DOI: 10.1021/acsmedchemlett.0c00393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Su M, Gong X, Liu F. An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. Expert Opin Drug Discov 2021;16:745-61. [PMID: 33530771 DOI: 10.1080/17460441.2021.1877656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Liu XJ, Xu-Liu, Pang XJ, -Ying Yuan X, Yu GX, Li YR, Guan YF, Zhang YB, Song J, Zhang QR, Zhang SY. Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy. Bioorg Med Chem 2021;47:116358. [PMID: 34479103 DOI: 10.1016/j.bmc.2021.116358] [Reference Citation Analysis]
19 Zhu F, Meng X, Liang H, Sheng C, Dong G, Liu D, Wu S. Design, Synthesis, and Structure-Activity relationships of Evodiamine-Based topoisomerase (Top)/Histone deacetylase (HDAC) dual inhibitors. Bioorganic Chemistry 2022;122:105702. [DOI: 10.1016/j.bioorg.2022.105702] [Reference Citation Analysis]
20 Li Y, Yang G, Yang C, Tang P, Chen J, Zhang J, Liu J, Ouyang L. Targeting Autophagy-Related Epigenetic Regulators for Cancer Drug Discovery. J Med Chem 2021;64:11798-815. [PMID: 34378389 DOI: 10.1021/acs.jmedchem.1c00579] [Reference Citation Analysis]
21 Li Y, Liu F, Liu W, Zhang Y, Tian X, Fu X, Xu Y, Song J, Zhang S. A novel aromatic amide derivative SY-65 co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo. Biochemical Pharmacology 2022;201:115070. [DOI: 10.1016/j.bcp.2022.115070] [Reference Citation Analysis]
22 Ojha R, Chen IC, Hsieh CM, Nepali K, Lai RW, Hsu KC, Lin TE, Pan SL, Chen MC, Liou JP. Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent. J Med Chem 2021;64:17824-45. [PMID: 34908406 DOI: 10.1021/acs.jmedchem.1c00966] [Reference Citation Analysis]
23 Chen X, He Y, Fu W, Sahebkar A, Tan Y, Xu S, Li H. Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review. Front Cell Dev Biol. 2020;8:581015. [PMID: 33282862 DOI: 10.3389/fcell.2020.581015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Schäker-Hübner L, Warstat R, Ahlert H, Mishra P, Kraft FB, Schliehe-Diecks J, Schöler A, Borkhardt A, Breit B, Bhatia S, Hügle M, Günther S, Hansen FK. 4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads. J Med Chem 2021;64:14620-46. [PMID: 34582215 DOI: 10.1021/acs.jmedchem.1c01119] [Reference Citation Analysis]
25 Filho EV, Pinheiro EM, Pinheiro S, Greco SJ. Aminopyrimidines: Recent synthetic procedures and anticancer activities. Tetrahedron 2021;92:132256. [DOI: 10.1016/j.tet.2021.132256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Ren Q, Gao W. Current status in the discovery of dual BET/HDAC inhibitors. Bioorg Med Chem Lett 2021;38:127829. [PMID: 33685790 DOI: 10.1016/j.bmcl.2021.127829] [Reference Citation Analysis]
27 Qiu X, Zhu L, Wang H, Tan Y, Yang Z, Yang L, Wan L. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy. Bioorg Med Chem 2021;52:116510. [PMID: 34826681 DOI: 10.1016/j.bmc.2021.116510] [Reference Citation Analysis]
28 Ran F, Liu Y, Xu Z, Meng C, Yang D, Qian J, Deng X, Zhang Y, Ling Y. Recent development of BTK-based dual inhibitors in the treatment of cancers. Eur J Med Chem 2022;233:114232. [PMID: 35247756 DOI: 10.1016/j.ejmech.2022.114232] [Reference Citation Analysis]
29 Szumilak M, Wiktorowska-Owczarek A, Stanczak A. Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance? Molecules 2021;26:2601. [PMID: 33946916 DOI: 10.3390/molecules26092601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Liang Q, Liu M, Li J, Tong R, Hu Y, Bai L, Shi J. NAE modulators: A potential therapy for gastric carcinoma. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114156] [Reference Citation Analysis]
31 Bass AKA, El-Zoghbi MS, Nageeb EM, Mohamed MFA, Badr M, Abuo-Rahma GEA. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. Eur J Med Chem 2021;209:112904. [PMID: 33077264 DOI: 10.1016/j.ejmech.2020.112904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Tang P, Zhang J, Liu J, Chiang CM, Ouyang L. Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development. J Med Chem 2021;64:2419-35. [PMID: 33616410 DOI: 10.1021/acs.jmedchem.0c01487] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
33 Chen L, Jin S, Gao J, Liu T, Shao Y, Feng J, Wang K, Lu T, Du D. N-Heterocyclic Carbene/Magnesium Cocatalyzed Radical Relay Assembly of Aliphatic Keto Nitriles. Org Lett 2021;23:394-9. [DOI: 10.1021/acs.orglett.0c03883] [Cited by in Crossref: 10] [Article Influence: 5.0] [Reference Citation Analysis]
34 Liang X, Tang S, Liu X, Liu Y, Xu Q, Wang X, Saidahmatov A, Li C, Wang J, Zhou Y, Zhang Y, Geng M, Huang M, Liu H. Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. J Med Chem 2021. [PMID: 33586434 DOI: 10.1021/acs.jmedchem.0c02111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Guo Z, Sun Y, Liang L, Lu W, Luo B, Wu Z, Huo B, Hu Y, Huang P, Wu Q, Wen S. Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors. J Med Chem 2022. [PMID: 35500243 DOI: 10.1021/acs.jmedchem.1c01876] [Reference Citation Analysis]
36 Ge J, Yin Y, Li Y, Deng Y, Fu H. Dual-target inhibitors based on PARP1: new trend in the development of anticancer research. Future Med Chem 2022. [PMID: 35257598 DOI: 10.4155/fmc-2021-0292] [Reference Citation Analysis]
37 Xiao Y, Zhang X. Recent advances in small molecular modulators targeting histone deacetylase 6. Future Drug Discovery 2020;2:FDD53. [DOI: 10.4155/fdd-2020-0023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Peng X, Chen J, Li L, Sun Z, Liu J, Ren Y, Huang J, Chen J. Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. J Med Chem 2021;64:8447-73. [PMID: 34097389 DOI: 10.1021/acs.jmedchem.1c00413] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Duan YC, Jin LF, Ren HM, Zhang SJ, Liu YJ, Xu YT, He ZH, Song Y, Yuan H, Chen SH, Guan YY. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer. Eur J Med Chem 2021;220:113453. [PMID: 33957387 DOI: 10.1016/j.ejmech.2021.113453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Zhang J, Luo Z, Duan W, Yang K, Ling L, Yan W, Liu R, Wüthrich K, Jiang H, Xie C, Cheng J. Dual-acting antitumor agents targeting the A2A adenosine receptor and histone deacetylases: Design and synthesis of 4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine derivatives. Eur J Med Chem 2022;236:114326. [PMID: 35390714 DOI: 10.1016/j.ejmech.2022.114326] [Reference Citation Analysis]